Toggle navigation
EN
Unternehmen
Über uns
Europäisches Partnernetzwerk
Engagement und Verantwortung
Frühe Nutzenbewertung und Erstattungsbetragsverhandlung
Europäische Nutzenbewertung (EU-HTA)
Statistik für Market Access
Festbeträge und Herstellerrabatte für Arzneimittel
Pricing & Reimbursement
Digitale Gesundheitsanwendungen (DiGA)
Publikationen
Aktuelle Publikationen
Frühe Nutzenbewertung
Erstattungsbetragsverhandlung
Europäische Nutzenbewertung (EU-HTA)
Statistik für Market Access
Festbeträge für Arzneimittel
Pricing & Reimbursement
Digitale Gesundheitsanwendungen (DiGA)
Medizinprodukte
Fach-Posts bei LinkedIn
Karriere
Arbeiten bei Ecker + Ecker
Bewerben bei Ecker + Ecker
Persönlichkeiten bei Ecker + Ecker
Aktuelles
zurück
EU-HTA
What to consider with a PICO proposal?
26.06.2025
PICO Proposal: A Key Advancement in PICO Scoping...
EU HTA: Impact to the Industry
24.06.2025
Preparing for Effective EU HTA Implementation: A Multi-Level Approach...
From Awareness to Action: Next Steps for EU HTA
17.06.2025
EU HTA Implementation: Progress & Perspectives...
EU HTA: State of Implementation
10.06.2025
EU HTA is to support local access. Hence implementation of EU HTA in the member states is essential....
Denmark joined our free quarterly newsletter for all the latest updates on HTA
13.05.2025
Get access to our latest update on HTA in Germany by Ecker + Ecker, Canada by MORSE Consulting Inc. and - just joined - Denmark by Zealth ...
Canada joined our free quarterly newsletter for all the latest updates on HTA
09.05.2025
Get access to our latest update on HTA in Germany by Ecker+Ecker and Canada by MORSE Consulting Inc. ...
Access Briefing: Germany Q4/24
11.04.2025
Get our latest update on HTA in Germany (AMNOG): ....
Lichtenstein, Norway and Iceland join the EU HTA family
03.04.2025
EU HTA Expands to 30 Countries! ...
New PICO Exercises Released: What Can We Learn?
01.04.2025
Evoque & PICO: Is One Enough? ...
New PICO Exercises Released: What Can We Learn?
19.03.2025
Why has publication taken that long? ...
New PICO Exercises Released: What Can We Learn?
14.03.2025
PICO Exercise for Accelerated Assessment!...
Key Updates on AMNOG & EU HTA Alignment
13.03.2025
Thrilling news ahead: the previously proposed 3-month suspension of the AMNOG process is not included in the final version of the First Regulation Amending the Ordinance on the Benefit Assessment of Medicinal Products...
← Zurück
1
(aktuell)
2
3
Vor →
Ansprechpartner
Dr. Thomas Ecker
Tel. +49 (40) 41 33 081-10
Janine Leismann
Tel. +49 (40) 41 33 081-26